Determination of Adrenergic and imidazoline receptor involvement in augmentation of morphine and oxycodone analgesia by clonidine and BMS182874

Pharmacology

Volumn 83, Issue 1, 2008, Pages 45-58

  Gulati, Anil ^a   Bhalla, Shaifali ^a   Matwyshyn, George ^a   Zhang, Zhong ^a   Andurkar, Shridhar V ^a  

^a MIDWESTERN UNIVERSITY   (United States)

Author keywords

Adrenergic receptors; Analgesia; Clonidine; Endothelin; Idazoxan; Imidazoline receptors; Morphine; Oxycodone; Yohimbine

Indexed keywords

5 DIMETHYLAMINO N (3,4 DIMETHYL 5 ISOXAZOLYL) 1 NAPHTHALENESULFONAMIDE; ALPHA 2 ADRENERGIC RECEPTOR; CLONIDINE; IMIDAZOLINE I1 RECEPTOR; MORPHINE; OXYCODONE;

ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; MALE; NONHUMAN; PAIN; PRIORITY JOURNAL; RAT; TAIL FLICK TEST;

ADRENERGIC ALPHA-AGONISTS; ANALGESICS, OPIOID; ANIMALS; AREA UNDER CURVE; CLONIDINE; DANSYL COMPOUNDS; DISEASE MODELS, ANIMAL; DRUG SYNERGISM; IDAZOXAN; IMIDAZOLINE RECEPTORS; MALE; MORPHINE; OXYCODONE; PAIN; PAIN MEASUREMENT; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ADRENERGIC, ALPHA-2; TIME FACTORS; YOHIMBINE;

EID: 57049115434     PISSN: 00317012     EISSN: None     Source Type: Journal    
DOI: 10.1159/000178812     Document Type: Article

References (59)

1. Knotkova H, Pappagallo M: Adjuvant analgesics. Med Clin North Am 2007;91:113-124.
2. Saarto T, Wiffen PJ: Antidepressants for neuropathic pain. Cochrane Database Syst Rev 2005:CD005454.
3. Rowbotham MC, Goli V, Kunz NR, Lei D: Venlafaxine extended release in the treatment of painful diabetic neuropathy: a double-blind, placebo-controlled study. Pain 2004;110:697-706.
4. Semenchuk MR, Sherman S, Davis B: Double-blind, randomized trial of bupropion SR for the treatment of neuropathic pain. Neurology 2001;57:1583-1588.
5. Backonja M, Beydoun A, Edwards KR, Schwartz SL, Fonseca V, Hes M, LaMoreaux L, Garofalo E: Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. JAMA 1998;280:1831-1836.
6. Gilron I, Bailey JM, Tu D, Holden RR, Weaver DF, Houlden RL: Morphine, gabapentin, or their combination for neuropathic pain. N Engl J Med 2005;352:1324-1334.
7. Bennett GJ: Update on the neurophysiology of pain transmission and modulation: focus on the NMDA-receptor. J Pain Symptom Manage 2000;19:S2-S6.
8. Paalzow L: Analgesia produced by clonidine in mice and rats. J Pharm Pharmacol 1974;26:361-363.
9. Ossipov MH, Lozito R, Messineo E, Green J, Harris S, Lloyd P: Spinal antinociceptive synergy between clonidine and morphine, U69593, and DPDPE: isobolographic analysis. Life Sci 1990;47:PL71-PL76.
10. Yaksh TL: Pharmacology of spinal adrenergic systems which modulate spinal nociceptive processing. Pharmacol Biochem Behav 1985;22:845-858.
11. Buerkle H, Yaksh TL: Pharmacological evidence for different alpha 2-adrenergic receptor sites mediating analgesia and sedation in the rat. Br J Anaesth 1998;81:208-215.
12. Fromm GH, Aumentado D, Terrence CF: A clinical and experimental investigation of the effects of tizanidine in trigeminal neuralgia. Pain 1993;53:265-271.
13. Goudas LC, Carr DB: Is there a place for intrathecal clonidine for clinical analgesia? Anesth Analg 1996;83:891.
14. Paalzow G: Development of tolerance to the analgesic effect of clonidine in rats: cross-tolerance to morphine. Naunyn Schmiedebergs Arch Pharmacol 1978;304:1-4.
15. Spaulding TC, Fielding S, Venafro JJ, Lal H: Antinociceptive activity of clonidine and its potentiation of morphine analgesia. Eur J Pharmacol 1979;58:19-25.
16. Gordon NC, Heller PH, Levine JD: Enhancement of pentazocine analgesia by clonidine. Pain 1992;48:167-169.
17. Constant I, Gall O, Gouyet L, Chauvin M, Murat I: Addition of clonidine or fentanyl to local anaesthetics prolongs the duration of surgical analgesia after single shot caudal block in children. Br J Anaesth 1998;80:294-298.
18. Hutschala D, Mascher H, Schmetterer L, Klimscha W, Fleck T, Eichler HG, Tschernko EM: Clonidine added to bupivacaine enhances and prolongs analgesia after brachial plexus block via a local mechanism in healthy volunteers. Eur J Anaesthesiol 2004;21:198-204.
19. 2+ channels. J Hypertens Suppl 1988;6:S188-S191.
20. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y, Goto K, Masaki T: A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988;332:411-415.
21. Benedict N, Seybert A, Mathier MA: Evidence-based pharmacologic management of pulmonary arterial hypertension. Clin Ther 2007;29:2134-2153.
22. Naeije R, Huez S: Expert opinion on available options treating pulmonary arterial hypertension. Expert Opin Pharmacother 2007;8:2247-2265.
23. Gulati A: Evidence for antagonistic activity of endothelin for clonidine induced hypotension and bradycardia. Life Sci 1992;50:153-160.
24. Gulati A, Rebello S, Roy S, Saxena PR: Cardiovascular effects of centrally administered endothelin-1 in rats. J Cardiovasc Pharmacol 1995;26(suppl 3):S244-S246.
25. Rebello S, Roy S, Saxena PR, Gulati A: Systemic hemodynamic and regional circulatory effects of centrally administered endothelin-1 are mediated through ETA receptors. Brain Res 1995;676:141-150.
26. MacCumber MW, Ross CA, Snyder SH: Endothelin in brain: receptors, mitogenesis, and biosynthesis in glial cells. Proc Natl Acad Sci USA 1990;87:2359-2363.
27. Sakurai T, Yanagisawa M, Takuwa Y, Miyazaki H, Kimura S, Goto K, Masaki T: Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptor. Nature 1990;348:732-735.
28. Jarvis MF, Wessale JL, Zhu CZ, Lynch JJ, Dayton BD, Calzadilla SV, Padley RJ, Opgenorth TJ, Kowaluk EA: ABT-627, an endothelin ET(A) receptor-selective antagonist, attenuates tactile allodynia in a diabetic rat model of neuropathic pain. Eur J Pharmacol 2000;388:29-35.
29. Wang X, Xu H, Rothman RB: Intracerebro-ventricular administration of anti-endothelin-1 igG selectively upregulates endothelin-A and kappa opioid receptors. Neuroscience 2004;129:751-756.
30. Wang X, Xu H, Rothman RB: Regulation of the rat brain endothelin system by endogenous beta-endorphin. Peptides 2006;27:769-774.
31. Bhalla S, Matwyshyn G, Gulati A: Potentiation of morphine analgesia by BQ123, an endothelin antagonist. Peptides 2002;23:1837-1845.
32. Bhalla S, Matwyshyn G, Gulati A: Endothelin receptor antagonists restore morphine analgesia in morphine tolerant rats. Peptides 2003;24:553-561.
33. Bhalla S, Matwyshyn G, Gulati A: Morphine tolerance does not develop in mice treated with endothelin-A receptor antagonists. Brain Res 2005;1064:126-135.
34. Gulati A, Bhalla S, Matwyshyn G: A novel combination of opiates and endothelin antagonists to manage pain without any tolerance development. J Cardiovasc Pharmacol 2004;44:S129-S131.
35. Matwyshyn GA, Bhalla S, Gulati A: Endothelin ETA receptor blockade potentiates morphine analgesia but does not affect gastrointestinal transit in mice. Eur J Pharmacol 2006;543:48-53.
36. Mutafova-Yambolieva V, Petkov O, Staneva-Stoytcheva D, Lasova L: Interactions between the effects of endothelin-1, clonidine and yohimbine on electrically-induced contractions in rat vas deferens. Gen Pharmacol 1992;23:529-534.
37. Gulati A, Srimal RC: Endothelin antagonizes the hypotension and potentiates the hypertension induced by clonidine. Eur J Pharmacol 1993;230:293-300.
38. Gulati A, Rebello S, Kumar A: Role of sympathetic nervous system in cardiovascular effects of centrally administered endothelin-1 in rats. Am J Physiol 1997;273:H1177-H1186.
39. Lim DY, Heo K, Choi CH, Lee EW: Influence of endothelin-1 on clonidine-induced cardiovascular effects in anesthetized rabbits. J Cardiovasc Pharmacol 1998;31(suppl 1):S122-S125.
40. D'Amour FE, Smith DL: A method for determining loss of pain sensation. J Pharmacol Exp Ther 1941;71:74-79.
41. Lahdesmaki J, Sallinen J, MacDonald E, Sirvio J, Scheinin M: Alpha2-adrenergic drug effects on brain monoamines, locomotion, and body temperature are largely abolished in mice lacking the alpha2a-adrenoceptor subtype. Neuropharmacology 2003;44:882-892.
42. Malmberg AB, Hedley LR, Jasper JR, Hunter JC, Basbaum AI: Contribution of alpha(2) receptor subtypes to nerve injury-induced pain and its regulation by dexmedetomidine. Br J Pharmacol 2001;132:1827-1836. 43 Ozdogan UK, Lahdesmaki J, Hakala K, Scheinin M: The involvement of alpha 2a-adrenoceptors in morphine analgesia, tolerance and withdrawal in mice. Eur J Pharmacol 2004;497:161-171.
43. Kaur R, Singh D, Chopra K: Participation of alpha2 receptors in the antinociceptive activity of quercetin. J Med Food 2005;8:529-532.
44. Roerig SC, Lei S, Kitto K, Hylden JK, Wilcox GL: Spinal interactions between opioid and noradrenergic agonists in mice: multiplicativity involves delta and alpha-2 receptors. J Pharmacol Exp Ther 1992;262:365-374.
45. Ordonez Gallego A, Gonzalez Baron M, Espinosa Arranz E: Oxycodone: a pharmacological and clinical review. Clin Transl Oncol 2007;9:298-307.
46. Benhamou D, Narchi P, Hamza J, Marx M, Peyrol MT, Sembeil F: Addition of oral clonidine to postoperative patient-controlled analgesia with i.v. morphine. Br J Anaesth 1994;72:537-540.
47. Jeffs SA, Hall JE, Morris S: Comparison of morphine alone with morphine plus clonidine for postoperative patient-controlled analgesia. Br J Anaesth 2002;89:424-427.
48. Nielsen CK, Ross FB, Lotfipour S, Saini KS, Edwards SR, Smith MT: Oxycodone and morphine have distinctly different pharmacological profiles: radioligand binding and behavioural studies in two rat models of neuropathic pain. Pain 2007;132:289-300.
49. Nozaki C, Kamei J: Involvement of mu1-opioid receptor on oxycodone-induced antinociception in diabetic mice. Eur J Pharmacol 2007;560:160-162.
50. Falk E: Eukodal ein neues Narkotikum (eukodal, a new narcotic). Muenchener Med Wochenschr 1917;64:381-384.
51. Yoburn BC, Shah S, Chan K, Duttaroy A, Davis T: Supersensitivity to opioid analgesics following chronic opioid antagonist treatment: relationship to receptor selectivity. Pharmacol Biochem Behav 1995;51:535-539.
52. Monory K, Greiner E, Sartania N, Sallai L, Pouille Y, Schmidhammer H, Hanoune J, Borsodi A: Opioid binding profiles of new hydrazone, oxime, carbazone and semicarbazone derivatives of 14-alkoxymorphinans. Life Sci 1999;64:2011-2020.
53. Peckham EM, Traynor JR: Comparison of the antinociceptive response to morphine and morphine-like compounds in male and female Sprague-Dawley rats. J Pharmacol Exp Ther 2006;316:1195-1201.
54. Ross FB, Smith MT: The intrinsic antinociceptive effects of oxycodone appear to be kappa-opioid receptor mediated. Pain 1997;73:151-157.
55. Gaveriaux-Ruff C, Kieffer BL: Opioid receptor genes inactivated in mice: the highlights. Neuropeptides 2002;36:62-71.
56. Pasternak GW: The pharmacology of mu analgesics: from patients to genes. Neuroscientist 2001;7:220-231.
57. Ernsberger P, Giuliano R, Willette RN, Reis DJ: Role of imidazole receptors in the vasodepressor response to clonidine analogs in the rostral ventrolateral medulla. J Pharmacol Exp Ther 1990;253:408-418.
58. 1-imidazoline sites. J Pharmacol Exp Ther 1993;264:172-182.
59. Hamilton CA, Yakubu MA, Jardine E, Reid JL: Imidazole binding sites in rabbit kidney and forebrain membranes. J Auton Pharmacol 1991;11:277-283.